Ryan-tech
Pharmaceuticals Sdn. Bhd. is a generic drug company which targets and produces
generic drugs for originally patented drugs that has its patent expired. The
company is currently working to produce a generic drug for olanzapine, with its
trade name Zyprexa, manufactured by Eli Lilly and Company, which has its patent
expired on April 23, 2011. A generic drug will be produced, and it will be
named Olanxa.
Olanzapine was formulated to serve
as a neuroleptic drug for bipolar disorder and schiziphrenia, which are types
of mental disorder. As the world population is growing, lifestyle in the
current society is getting a faster pace day by day, as well as with increasing
stress and burden. The increase of living cost, the pressure from work and
family, as well as the stress from all other sources are some major cause of
bipolar disorder and schizophrenia as well as some other mental illness. The
ultimate goal of the company is to produce a generic drug based on olanzapine
which can effectively treat and control the effects of bipolar disorder and
schizophrenia on its patient compared with its original drugs and other future
generics.
This company was co-founded on 2nd
November, 2011 from a partnership between academic researcher Dr. See Woan Yueh
and her research team with venture capitalist Mr. Ryan Chong Wai Kit. Currently
the ownership of the company was shared among the two individual mentioned
above.
Currently the corporal and
management affairs of the company are being managed by one of the owner and
co-founder of the company, Mr. Ryan Chong Wai Kit as the Chief Executive
Officer (CEO) with the help of a Chief Financial Officer (CFO) to advice and
manage issues regarding financial affairs. Another co-founder and partner, Dr.
See Woan Yue will involve in coordinating the scientific research and
production line as the post of Chief Scientific Officer (CSO).
